Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.

Romero-Laorden, NPiñeiro-Yañez, EGutierrez-Pecharroman, APacheco, M ICalvo, EAl-Shahrour, FCastro, EOlmos, D2023-01-252023-01-252017http://hdl.handle.net/10668/11146enAgedBRCA2 ProteinBenzimidazolesGenes, BRCA2Germ-Line MutationHumansLoss of HeterozygosityMalePoly(ADP-ribose) Polymerase InhibitorsProstatic Neoplasms, Castration-ResistantSomatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.research article28453706open access10.1093/annonc/mdx0671569-8041https://doi.org/10.1093/annonc/mdx067